TR study of "A multicenter phase II study of eribulin monotherapy in patients with BRAF V600E mutant metastatic colorectal cancer (BRAVERY study)"
Not Applicable
- Conditions
- BRAF V600E mutant metastatic colorectal cancer
- Registration Number
- JPRN-UMIN000031552
- Lead Sponsor
- Aichi Cancer Center Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 27
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method cancer-related gene alteration, gene expression, microsatellite instability, BRAF mutant allele frequency
- Secondary Outcome Measures
Name Time Method